+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Op-7 Therapeutic Effects Of Domperidone On Abdominal Pain-Predominant Functional Gastrointestinal Disorders: Randomized, Double-Blind, Placebo- Controlled Trial



Op-7 Therapeutic Effects Of Domperidone On Abdominal Pain-Predominant Functional Gastrointestinal Disorders: Randomized, Double-Blind, Placebo- Controlled Trial



Journal of Pediatric Gastroenterology and Nutrition 61(4): 511-512



The therapeutic effect of domperidone on abdominal pain-predominant functional gastrointestinal diseases (AP-FGIDs) was assessed on children in 5-12 year age group at the Gastroenterology Research Laboratory of Faculty of Medicine, University of Kelaniya, Sri Lanka. Children fulfilling Rome III criteria for AP-FGIDs were recruited from the out-patient clinic of the University Paediatric Unit, North Colombo Teaching Hospital, Ragama, Sri Lanka, after obtaining parental consent. They were randomized in to 8 weeks of placebo or Domperidone (Motillium 10 mg, 3 times per day, before meals) groups, using computer generated random numbers. Placebo was a specially prepared dummy tablet without any active ingredients, had the same colour, size, shape and taste of domperidone tablet and were packaged similarly. Primary outcomes defined were cure (abdominal pain less than 25 mm on the visual analogue scale and no impact on daily activities) and improvement (pain relief and sense of improvement recorded on global assessment scale). Secondary outcomes were significant improvement in symptoms, gastric motility, quality of life (QoL) and family impact. Both patients and investigators who assessed primary and secondary outcomes before and after intervention were blind to inventions administered. Symptom severity was recorded on a validated 100 mm visual analogue scale. Translated and validated PedQL Generic Score Scale version 4.0 and Family Impact Module were used. Gastric motility was assessed using a validated ultrasound method. One hundred children were enrolled and 89 completed the trial [Placebo 42 (22 girls), Domperidone 47(33 girls)]. While comparing primary outcomes, domperidone group had significant improvement [37 (78.7%) vs. 25 (59.5%) in placebo group, p = 0.04], while no such difference was observed in cure. When assessing secondary outcomes, domperidone group reported significant reduction in abdominal pain severity (70.84% vs. 48.18% p = 0.03) and improvement in motility index (29.3% vs. 8.6% p = 0.04) after intervention. No such difference was seen in improvement of QoL and family impact (p > 0.05). Domperidone has a favorable therapeutic effect on improvement AP-FGIDs in children aged 5-12 years. It causes significant reduction in abdominal pain and improvement in motility of the gastric antrum. However, it has no significant effect on improvement of QoL and family impact.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058461576

Download citation: RISBibTeXText

PMID: 26439548

DOI: 10.1097/01.mpg.0000472211.46517.33


Related references

A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Alimentary Pharmacology and Therapeutics 25(2): 177-184, 2007

Randomized double blind placebo-controlled trial of Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: improvement in abdominal pain and bloating in those with predominant constipation. United European Gastroenterology Journal 4(3): 353-362, 2016

A Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus reuteri for Chronic Functional Abdominal Pain in Children. Iranian Journal of Pediatrics 25(6): E2616, 2015

Lactobacillus reuteri DSM 17938 for the Management of Functional Abdominal Pain in Childhood: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Pediatrics 174: 160-164.E1, 2017

Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomised, double-blind, sham-controlled trial. Lancet. Gastroenterology and Hepatology 2(10): 727-737, 2017

A Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial of Qi-Zhi-Wei-Tong Granules on Postprandial Distress Syndrome-Predominant Functional Dyspepsia. Chinese Medical Journal 131(13): 1549-1556, 2018

Pregabalin for the treatment of abdominal adhesion pain: a randomized, double-blind, placebo-controlled trial. American Journal of Therapeutics 19(6): 419-428, 2013

A randomized, double blind, placebo controlled trial of domperidone in lactating mothers of premature newborns. Clinical Pharmacology & Therapeutics 65(2): 176, 1999

Effectiveness of intravenous magnesium on postoperative pain after abdominal surgery versus placebo: double blind randomized controlled trial. La Tunisie Medicale 88(5): 317-323, 2010

Double-blind, placebo-controlled, randomized clinical trial of homoeopathic arnica C30 for pain and infection after total abdominal hysterectomy. Journal of the Royal Society of Medicine 90(2): 73-78, 1997

Double blind randomized placebo controlled trial for the evaluation of domperidone in the treatment of children with gastroesophageal reflux. Gastroenterology 98(5 Part 2): A21, 1990

Symptomatic response to Helicobacter pylori eradication in children with recurrent abdominal pain: double blind randomized placebo-controlled trial. Journal of Clinical Gastroenterology 38(8): 646-650, 2004

A randomized, double-blind, placebo-controlled trial to assess the essentiality of acid inhibitors for abdominal pain after gastroscopic mucosal biopsy. Turkish Journal of Gastroenterology 24(3): 197-203, 2014

Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. European Journal of Endocrinology 166(4): 601-611, 2012

Duloxetine versus placebo for the treatment of women with stress predominant urinary incontinence in Taiwan: a double-blind, randomized, placebo-controlled trial. Bmc Urology 8: 2, 2008